Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts

Shen Li, Byoung Chol Oh, Chengyan Chu, Antje Arnold, Anna Jablonska, Georg J. Furtmüller, Hua Min Qin, Johannes Boltze, Tim Magnus, Peter Ludewig, Mirosław Janowski, Gerald Brandacher, Piotr Walczak

Research output: Contribution to journalArticle

Abstract

The immunological barrier currently precludes the clinical utilization of allogeneic stem cells. Although glial-restricted progenitors have become attractive candidates to treat a wide variety of neurological diseases, their survival in immunocompetent recipients is limited. In this study, we adopted a short-term, systemically applicable co-stimulation blockade-based strategy using CTLA4-Ig and anti-CD154 antibodies to modulate T-cell activation in the context of allogeneic glial-restricted progenitor transplantation. We found that co-stimulation blockade successfully prevented rejection of allogeneic glial-restricted progenitors from immunocompetent mouse brains. The long-term engrafted glial-restricted progenitors myelinated dysmyelinated adult mouse brains within one month. Furthermore, we identified a set of plasma miRNAs whose levels specifically correlated to the dynamic changes of immunoreactivity and as such could serve as biomarkers for graft rejection or tolerance. We put forward a successful strategy to induce alloantigen-specific hyporesponsiveness towards stem cells in the CNS, which will foster effective therapeutic application of allogeneic stem cells.

Original languageEnglish (US)
Pages (from-to)3456-3472
Number of pages17
JournalBrain : a journal of neurology
Volume142
Issue number11
DOIs
StatePublished - Nov 1 2019

Fingerprint

Neuroglia
Allografts
Stem Cells
Transplantation Tolerance
Isoantigens
Brain
Graft Rejection
MicroRNAs
Anti-Idiotypic Antibodies
Transplantation
Biomarkers
T-Lymphocytes
Therapeutics

Keywords

  • co-stimulation blockade
  • glial-restricted progenitors
  • immunological tolerance
  • myelination
  • transplantation

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts. / Li, Shen; Oh, Byoung Chol; Chu, Chengyan; Arnold, Antje; Jablonska, Anna; Furtmüller, Georg J.; Qin, Hua Min; Boltze, Johannes; Magnus, Tim; Ludewig, Peter; Janowski, Mirosław; Brandacher, Gerald; Walczak, Piotr.

In: Brain : a journal of neurology, Vol. 142, No. 11, 01.11.2019, p. 3456-3472.

Research output: Contribution to journalArticle

Li, S, Oh, BC, Chu, C, Arnold, A, Jablonska, A, Furtmüller, GJ, Qin, HM, Boltze, J, Magnus, T, Ludewig, P, Janowski, M, Brandacher, G & Walczak, P 2019, 'Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts', Brain : a journal of neurology, vol. 142, no. 11, pp. 3456-3472. https://doi.org/10.1093/brain/awz275
Li, Shen ; Oh, Byoung Chol ; Chu, Chengyan ; Arnold, Antje ; Jablonska, Anna ; Furtmüller, Georg J. ; Qin, Hua Min ; Boltze, Johannes ; Magnus, Tim ; Ludewig, Peter ; Janowski, Mirosław ; Brandacher, Gerald ; Walczak, Piotr. / Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts. In: Brain : a journal of neurology. 2019 ; Vol. 142, No. 11. pp. 3456-3472.
@article{bb7e8861e6954b0fbea71671d1f2f31e,
title = "Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts",
abstract = "The immunological barrier currently precludes the clinical utilization of allogeneic stem cells. Although glial-restricted progenitors have become attractive candidates to treat a wide variety of neurological diseases, their survival in immunocompetent recipients is limited. In this study, we adopted a short-term, systemically applicable co-stimulation blockade-based strategy using CTLA4-Ig and anti-CD154 antibodies to modulate T-cell activation in the context of allogeneic glial-restricted progenitor transplantation. We found that co-stimulation blockade successfully prevented rejection of allogeneic glial-restricted progenitors from immunocompetent mouse brains. The long-term engrafted glial-restricted progenitors myelinated dysmyelinated adult mouse brains within one month. Furthermore, we identified a set of plasma miRNAs whose levels specifically correlated to the dynamic changes of immunoreactivity and as such could serve as biomarkers for graft rejection or tolerance. We put forward a successful strategy to induce alloantigen-specific hyporesponsiveness towards stem cells in the CNS, which will foster effective therapeutic application of allogeneic stem cells.",
keywords = "co-stimulation blockade, glial-restricted progenitors, immunological tolerance, myelination, transplantation",
author = "Shen Li and Oh, {Byoung Chol} and Chengyan Chu and Antje Arnold and Anna Jablonska and Furtm{\"u}ller, {Georg J.} and Qin, {Hua Min} and Johannes Boltze and Tim Magnus and Peter Ludewig and Mirosław Janowski and Gerald Brandacher and Piotr Walczak",
year = "2019",
month = "11",
day = "1",
doi = "10.1093/brain/awz275",
language = "English (US)",
volume = "142",
pages = "3456--3472",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts

AU - Li, Shen

AU - Oh, Byoung Chol

AU - Chu, Chengyan

AU - Arnold, Antje

AU - Jablonska, Anna

AU - Furtmüller, Georg J.

AU - Qin, Hua Min

AU - Boltze, Johannes

AU - Magnus, Tim

AU - Ludewig, Peter

AU - Janowski, Mirosław

AU - Brandacher, Gerald

AU - Walczak, Piotr

PY - 2019/11/1

Y1 - 2019/11/1

N2 - The immunological barrier currently precludes the clinical utilization of allogeneic stem cells. Although glial-restricted progenitors have become attractive candidates to treat a wide variety of neurological diseases, their survival in immunocompetent recipients is limited. In this study, we adopted a short-term, systemically applicable co-stimulation blockade-based strategy using CTLA4-Ig and anti-CD154 antibodies to modulate T-cell activation in the context of allogeneic glial-restricted progenitor transplantation. We found that co-stimulation blockade successfully prevented rejection of allogeneic glial-restricted progenitors from immunocompetent mouse brains. The long-term engrafted glial-restricted progenitors myelinated dysmyelinated adult mouse brains within one month. Furthermore, we identified a set of plasma miRNAs whose levels specifically correlated to the dynamic changes of immunoreactivity and as such could serve as biomarkers for graft rejection or tolerance. We put forward a successful strategy to induce alloantigen-specific hyporesponsiveness towards stem cells in the CNS, which will foster effective therapeutic application of allogeneic stem cells.

AB - The immunological barrier currently precludes the clinical utilization of allogeneic stem cells. Although glial-restricted progenitors have become attractive candidates to treat a wide variety of neurological diseases, their survival in immunocompetent recipients is limited. In this study, we adopted a short-term, systemically applicable co-stimulation blockade-based strategy using CTLA4-Ig and anti-CD154 antibodies to modulate T-cell activation in the context of allogeneic glial-restricted progenitor transplantation. We found that co-stimulation blockade successfully prevented rejection of allogeneic glial-restricted progenitors from immunocompetent mouse brains. The long-term engrafted glial-restricted progenitors myelinated dysmyelinated adult mouse brains within one month. Furthermore, we identified a set of plasma miRNAs whose levels specifically correlated to the dynamic changes of immunoreactivity and as such could serve as biomarkers for graft rejection or tolerance. We put forward a successful strategy to induce alloantigen-specific hyporesponsiveness towards stem cells in the CNS, which will foster effective therapeutic application of allogeneic stem cells.

KW - co-stimulation blockade

KW - glial-restricted progenitors

KW - immunological tolerance

KW - myelination

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=85074305522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074305522&partnerID=8YFLogxK

U2 - 10.1093/brain/awz275

DO - 10.1093/brain/awz275

M3 - Article

C2 - 31529023

AN - SCOPUS:85074305522

VL - 142

SP - 3456

EP - 3472

JO - Brain

JF - Brain

SN - 0006-8950

IS - 11

ER -